A new generation of vaccine manufacturing is rising
Years of experience
The “LEEI Consortium” is an interdisciplinary collaboration between the various partners of KyooBe Tech, Bausch+Ströbel and four Fraunhofer Research Institutes.
We use, in a new and innovative approach, electron beams instead of toxic chemicals for pathogen inactivation. This increases time-efficiency of production, vaccine quality and process reproducibility.
Thanks to the interdisciplinary structure of the team, KyooBe Tech can further advance process-oriented optimization and system integration as well as market adaptation for customers.
Bausch+Ströbel is a trusted and experienced supplier to the pharmaceutical industry specializing in filling and packaging systems.
B+S‘s expertise in the development and manufacture of high-precision machines for pharmaceutical production forms an important basis for the high quality standards that apply to pharmaceuticals such as Vaccines.
A group of four Fraunhofer institutes are scientific pioneers for this technology. They contiously develop and elaborate new fields of application of LEEI-technologies. They conduct extensive studies on pathogenes to develop future vaccine candidates. The Fraunhofer institutes are in charge of the prototype system.
Since 2014, they have been developing the foundations for patented technology and scientific evidence for its effectiveness in various applications.
In addition, the Bill & Melinda Gates Foundation invested USD 1.85 million for the second phase of the technology roadmap.
The start of journey
First experiments, regarding Low-energy electron irradiation (LEEI), were performed by Fraunhofer cooperation of institutes FEP and IZI.
First virus inactivation
LEEI-based inactivation of viruses (PRRSV and Influenza A) by Fraunhofer institutes IZI and FEP.
Design of large-scale tech innovation project
Four Fraunhofer institutes (Fraunhofer FEP, IGB, IPA, IZI) are joining forces within in interdisciplinary research approach.
Innovation project granted
Project is founded by Fraunhofer innovation funds for 36 month period to speed up technology development and transfer. The focus of the project was set to examine the basic method of irradiating pathogen substances.
Filing of ELVIRA patent familiy (WO2015011265A1)
The technology is registered for a patent because of its novelty and uniqueness.
Grant by Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation believes in potential of LEEI for vaccine manufacturing and finances a second project phase by USD 1.85 million. Fraunhofer FEP and Fraunhofer IPA jointly develope the basics of an automated irradiation system. This experimental base is installed at the Fraunhofer IZI in Leipzig by autumn 2018.
First scientific publications of pathogen inactication by LEEI
• 2016: Escherichia coli, porcine reproductive and respiratory syndrome virus (PRRSV), equine herpesvirus 1 (EHV-1), influenza A (H3N8)
• 2018: respiratory syncytial virus (RSV)
• 2018: publication of WO2018041953A1
• 2019: Eimeria tenella
• 2020: Rodentibacter pneumotropicus
Licensing deal with Bausch+Ströbel
Cutting-edge technology needs excellent partners to foster their global distribution and applicability. Thus Fraunhofer and global partner for fill & finish Bausch+Ströbel joined forces in a strategic partnership.
Foundation of KyooBe Tech GmbH
KyooBe was founded as a spin-off by Bausch + Ströbel in order to make LEEI ready for pharmaceutical manufacturing. KyooBe brings together the know-how and the skills of a talented and highly diverse team.
Present ELLI 2.0 Prototype
Together with strong partners from science and practice, the technology is further developed and converted into a compact and scalable product prototype.
The goal is to ensure the technological implementation and marketability of the manufacturing technology by that time.
Parcipitate in a new generation of vacccine manufacturing!
Get in contact to learn and participate!